Ken Griffin Exicure, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Exicure, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 18,159 shares of XCUR stock, worth $5,992. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,159Holding current value
$5,992% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding XCUR
# of Institutions
21Shares Held
860KCall Options Held
0Put Options Held
0-
Abingworth LLP London, X0282KShares$92,9390.11% of portfolio
-
Carlyle Group Inc. Washington, DC282KShares$92,9390.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny65.6KShares$21,6480.0% of portfolio
-
Geode Capital Management, LLC Boston, MA56.5KShares$18,6510.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.1KShares$13,2300.0% of portfolio
About EXICURE, INC.
- Ticker XCUR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 4,962,580
- Market Cap $1.64M
- Description
- Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie...